Trelagliptin

Nomen chemicum:

(R) -2-((6-(3-aminopiperidin-1-yl) -3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinatum

SMILES Code:

N#CC1=CC=C(F)C=C1CN(C(N2C)=O)C(N3C[C@H](N)CCC3)=CC2=O

InChi Code:

InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(233-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14( 19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1

InChi Key:

IWYJYHUNXVAVAA-OAHLLOKOSA-N

Keyword:

Trelagliptin, Trelagliptin succinata, SYR-472, Zafatek, 865759-25-7, 1029877-94-8

Solubilitas:Solutum in DMSO

Repono:0 - 4°C ad terminum brevem (dies ad septimanas), vel -20°C ad terminum longi (menses).

Descriptio:

Trelagliptin, quod etiam SYR-472 notum est, longum est dipeptidylum peptidase-4 (DPP-4) inhibitor, qui ab Takeda amplificatur ad tractationem diabetis speciei 2 (T2D). Aliquando hebdomade SYR-472 curatio effecta est amet emendatio et peraeque signanter in glycemica potestate aegros cum 2 diabete typus. Optionem patientibus hoc morbo novas curationes toleravit. Trelagliptin (Zafatek(®)) probatus est in Iaponia ad tractationem speciei 2 diabete melliti (T2DM).

Target: DPP-4